Day: March 29, 2020

Banco Comercial Português, S.A., informs about 2019 Annual ReportAttachmentRABCP2019_EN

Banco Comercial Português, S.A., informa sobre Relatório e Contas de 2019AnexoRCBCP2019_PT

ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication Medtronic Receives FDA “Breakthrough Device Designation” for Symplicity Spyral™ Renal Denervation SystemDUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial. The prospectively powered study of patients with uncontrolled high blood pressure (BP) not taking anti-hypertensive medications met its primary and secondary effectiveness endpoints, with a >99.9% probability of superiority for both versus those who received a sham control procedure. Additionally, there were no major device or procedural safety events through three months. The study was presented today as part of the...

ACC.20/WCC: Low Rates of Paravalvular Leak and High Survival Observed in Late-breaking Clinical Trial of Low-Risk Bicuspid Aortic Stenosis PatientsDUBLIN, March 29, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced late-breaking clinical data from the Low Risk Bicuspid Study assessing the use of the Evolut™ transcatheter aortic valve replacement (TAVR) system in patients with bicuspid aortic valve stenosis at low surgical risk. The study showed low rates of all-cause mortality or stroke at 30 days (1.3%) with a low rate of serious procedural complications, and no annular rupture or aortic dissection. The study was presented as part of the American College of Cardiology together with World Congress of Cardiology Scientific Sessions (ACC.20/WCC) meeting.Results from the 150-patient,...

The Company announces decisions made today during the meeting of the Supervisory Council regarding changes in the Management Board and the Supervisory Council. Birutė Čepanskienė, a member of the Management Board and Chief Commercial Officer will be replaced by Ieva Galvydiene starting from 1st April. B. Čepanskienė is leaving the Board due to personal circumstances.I. Galvydienė has great experience in the tourism industry, especially in sales and commerce. She has been with the Novaturas Group for 13 years and has been leading the Sales department in Lithuania for 8 years, also coordinating commerce in other markets. Since November 2019, I. Galvydienė has been heading the Aviation Division at Novaturas Group. The Company continues to follow the strategy of having long-term executives with excellent know-how, multiple years of experience...

Bendrovė praneša apie šiandien vykusiame Stebėtojų tarybos posėdyje priimtus sprendimus dėl pokyčių valdyboje ir stebėtojų taryboje.Bendrovės valdybos narę Birutę Čepanskienę nuo balandžio 1 d. keičia Ieva Galvydienė. B. Čepanskienė valdybą palieka dėl asmeninių aplinkybių. I. Galvydienė nuo balandžio 1 d. perims ir „Novaturo“ grupės Komercijos vadovės pareigas.I Galvydienė yra sukaupusi daug turizmo industrijos patirties, ypač – pardavimų, komercijos srityse. „Novaturo“ grupėje ji dirba jau 13 metų, 8-erius iš jų vadovavo Pardavimų skyriui Lietuvoje, koordinavo pardavimus kitose rinkose. Nuo praėjusių metų lapkričio I. Galvydienė vadovauja „Novaturo“ grupės Aviacijos skyriui.Įmonė ir toliau laikosi strategijos, kad bendrovės valdyboje dirbtų ilgamečiai įmonės vadovai, sukaupę daug praktinių žinių, daugybės metų patirtį turizmo rinkoje...